|
Characteristic
|
All patients n = 621
|
Usual care n = 319 (51 %)
|
Monitoring n = 302 (49 %)
|
p value
|
|---|
|
Medication
| | | | |
|
ACE inhibitor/ARB, n (%)
|
577 (93)
|
297 (93)
|
280 (93)
|
0.974
|
|
Beta blocker – number/total number (%)
|
591/620 (95)
|
303/319 (95)
|
288/301 (96)
|
0.826
|
|
MR antagonist, n (%)
|
439 (71)
|
232 (73)
|
207 (69)
|
0.291
|
|
Diuretics, n (%)
|
506 (82)
|
255 (80)
|
251 (83)
|
0.360
|
|
Glycosides, n (%)
|
95 (15)
|
50 (16)
|
45 (15)
|
0.876
|
|
Amiodarone, n (%)
|
80 (13)
|
48 (15)
|
32 (11)
|
0.125
|
|
Anticoagulation, n (%)
| | | | |
|
Vitamin K antagonist
|
231 (37)
|
122 (38)
|
109 (36)
|
0.637
|
|
Other
|
42 (7)
|
24 (8)
|
18 (6)
|
0.538
|
|
Devices, n (%)
| | | | |
|
Pacemaker
|
101 (16)
|
61 (19)
|
40 (13)
|
0.061
|
|
ICD
| | | |
0.280
|
|
with monitoring
|
63 (10)
|
31 (10)
|
32 (11)
| |
|
without monitoring
|
242 (39)
|
134 (42)
|
108 (36)
| |
|
CRT-D
|
89 (14)
|
40 (13)
|
49 (16)
|
0.232
|
- ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CRT-D cardiac resynchronization therapy combined with defibrillation ICD implantable cardioverter defibrillator, MR mineralocorticoid receptor
